Clinical trials: MAFLD
Hepatic Disorders, Intestinal Failure-associated Liver Disease
VALidation of Imaging-based Liver Biomarkers in PEDiatric Patients
The goal of this observational (diagnostic validation) study is to validate imaging-based biomarkers for assessing liver involvement in pediatric patients with established or suspected liver disease.
- Conditions
- Hepatic Disorders, Intestinal Failure-associated Liver Disease, Cystic Fibrosis Liver Disease, MAFLD
- Trial name
- VALiBi-PED (NCT07202910)
- Where
- Sweden
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Sahlgrenska University Hospital
MAFLD
Diacerein in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common chronic progressive liver disease in China, posing a significant risk for hepatic decompensation, cardiovascular disease (CVD), chronic kidney…
- Trial name
- NCT07199933
- Testing
- Diacerein 50 mg Capsule
- Volunteers
- 74 people
- Sponsor
- Hongyan Wu
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL), Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- HEPACT (NCT07068191)
- Testing
- Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Phenomen Pharma
MAFLD
Clinical Study on the Treatment of MAFLD With Ganzhixiao Capsules
This trial is expected to enroll 138 MAFLD patients in one clinical center, who will be randomly divided into a placebo group and a Ganzhixiao capsule group in a 1:1 ratio.
- Trial name
- NCT06848907
- Testing
- ganzhixiao capsule
- Volunteers
- 138 people
- Sponsor
- Dong Hui
Metabolic-dysfunction-associated Fatty Liver Disease (MAFLD)
Optimal Measurement of Spleen Stiffness Among Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease
A growing number of people are being diagnosed with fatty liver disease, also known as metabolic-dysfunction associated liver disease (MASLD).
- Trial name
- NCT06953830
- Testing
- Vibration-controlled transient elastography
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- William Jennings Bryan Dorn VA Medical Center
Metabolic-associated Fatty Liver Disease (MAFLD)
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
Metabolic-associated fatty liver disease (MAFLD) is a chronic progressive liver disease caused by nutrient excess and insulin resistance (IR) in genetically susceptible individuals.
- Trial name
- NCT06798948
- Testing
- Combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Li Lab,MD
MAFLD
Glucose Disposal Rate as a Metric for Detection of Metabolic Associated Fatty Liver
A 12-month prospective observational cohort study assessing eGDR's utility in diagnosing MAFLD (via FibroScan® CAP ≥248 dB/m) and correlating it with steatosis/fibrosis severity.
- Trial name
- NCT06923215
- Volunteers
- 30 people
- Sponsor
- Assiut University
Metabolic- Associated Fatty Liver Disease (MAFLD)
MAFLD Fibrosis Score for Detecting Fibrotic NASH in MAFLD Egyptian Patients
Metabolic-associated fatty liver disease (MAFLD), is a metabolic stress-induced liver injury characterized by diffuse hepatocyte macrovesicular fatty infiltration.
- Trial name
- NCT06492369
- Where
- Egypt
- Volunteers
- 382 people
- Sponsor
- Tanta University
Detect the Significance of Remnant Cholesterol in Detection Severity of MAFLD
The Significance of Remnant Cholesterol and Carotid Intima Media Thickness in Patients With MAFLD
1. To detect the significance of remenant cholesterol in detection severity of MAFLD 2. To detect the significance of carotid intima-media thickness in MAFLD
- Trial name
- MAFLD (NCT06449092)
- Testing
- Lipid profile
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Mafld in Ckd Patients
Association Betweenq MAFLD ( Metabolic Associated Fatty Liver Disease) and Chronic Kidney Disease
Assess frequency of renal affection in mafld
- Trial name
- NCT06135467
- Volunteers
- 150 people
- Sponsor
- Assiut University
Metabolic-associated Fatty Liver Disease (MAFLD)
Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study
The goal of this observational study is to learn the effectiveness and safety of the use of Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the pathogenetic therapy of metabolic-associated fatty liver disease…
- Trial name
- NCT06078722
- Where
- 7 sites in Kazakhstan
- Volunteers
- 264 people
- Sponsor
- Kazakh Association of Internal Medicine Specialists
Metabolic-dysfunction-associated Fatty Liver Disease (MAFLD)
Noninvasive Assessment of Metabolic Associated Fatty Liver Disease (MAFLD) in Chinese Population
Attenuation imaging (ATI) technology independently developed by Canon medical is a non-invasive examination technology for quantitative detection and analysis of liver steatosis.
- Trial name
- NCT04551716
- Where
- China
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
NAFLD/MAFLD, Liver Fibrosis
Impact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.
Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.
- Conditions
- NAFLD/MAFLD, Liver Fibrosis, CMR
- Trial name
- NCT05239260
- Testing
- CMR
- Where
- Austria
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna